Additionally, previous studies have demonstrated the robust performance of MRI-based radiomics biomarkers in predicting PD-L1 expression levels across various tumor type including hepatocellular carcinoma, cholangiocarcinoma and breast cancer (15, 23, 24). Here, CD274 is linked to breast cancer.